Fibrogen investors’ nerves jangle as another key cardiovascular safety readout approaches for the anaemia project.
Nucana’s recent setback with Acelarin adds to the long list of pancreatic cancer failures, and a look at the late-stage pipeline shows little concrete progress.
The cystic fibrosis player does deals with Crispr and Exonics to launch itself into a highly competitive rare disease area.
Fibrogen tumbles on a confusing safety update for its most advanced project.
Questions about Akebia's disclosure of liver toxicity in a trial raise a red flag over vadadustat, the company's experimental anaemia treatment.
Duchenne muscular dystrophy attracts a new entrant in pamrevlumab, while Alnylam awaits more pivotal data with givosiran.
A look at the biggest potential drug launches this year reveals a long list of blockbusters from the likes of Alexion and Abbvie. But what impact will the shutdown have?
Fibrogen’s roxadustat has its first European win from the Alps trial, but the most important event is still to come.
Annual analysis shows a new crop of biotech assets with ballooning valuations and no major partners.